80 completed, 3 unknown, 2 recruiting, 2 terminated. 88 Phase 2, 6 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 88 | Completed 80, Unknown 3, Recruiting 2, Terminated 2, Active not recruiting 1 |
| Phase 3 | 6 | Completed 4, Recruiting 1, Unknown 1 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
Follow Meningococcal Infections: new trials by email Literature Review of Meningococcal Infections trials Research Report on Meningococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old EG-MCV4, Menveo - Meningococcal Infections | Phase 2 / Phase 3 | Recruiting | EyeGene Inc. | 1123 | 2025-10-15 | 2025-12-01 |
| Azithromycin for Meningococcal Carriage Azithromycin - Meningococcal Infections | Phase 2 | Completed | Emory University | 764 | 2024-11-12 | 2026-06-05 |
| A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, ACYW135 Meningococcal Polysaccharide Vaccine - Meningococcal Meningitis | Phase 2 | Unknown | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | 1200 | 2024-03-20 | 2024-03-29 |
| Meningococcal B Vaccine in Patients with Asplenia Bexsero - Splenectomy; Status | Phase 2 | Recruiting | Medical University of Vienna | 80 | 2024-03-12 | 2024-11-22 |
| A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants MenACWY-7B low dose vaccine, MenACWY-7B high dose vaccine, MenABCWY-1Gen vaccine - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 726 | 2021-11-29 | 2026-06-26 |
| Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents MenABCWY vaccine, Placebo - Meningitis, Meningococcal | Phase 2 | Active not recruiting | GlaxoSmithKline | 305 | 2021-11-18 | 2026-09-28 |
| A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo - Infections, Meningococcal | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1440 | 2021-06-14 | 2025-05-31 |
| Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 2 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 720 | 2018-12-21 | 2022-02-25 |
| Conjugate Vaccine Against Meningococcus C a Brazilian Project MenCC-BIO Vaccine, Combined - CRM197 - Serogroup C Meningococcal Meningitis | Phase 2 / Phase 3 | Unknown | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 1644 | 2018-09-25 | 2018-10-10 |
| A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A), Licensed GSK MenACWY vaccine (Menveo) - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 996 | 2018-09-07 | 2021-02-09 |
| A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age MenACWY liquid, MenACWY - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1707 | 2018-08-30 | 2021-02-17 |
| Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years MenABCWY vaccine, rMenB+OMV NZ (Bexsero) vaccine, MenACWY (Menveo) vaccine - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 520 | 2018-07-09 | 2020-02-12 |
| Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds Non-adjuvanted study formulation NmCV-5, Adjuvanted study formulation NmCV-5, Menactra - Meningitis, Meningococcal | Phase 2 | Completed | Serum Institute of India Pvt. Ltd. | 375 | 2017-11-15 | 2025-05-25 |
| Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents Meningococcal ABCWY Vaccine, Meningococcal B Recombinant vaccine - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 604 | 2016-11-15 | 2019-08-20 |
| Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free), Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant) - Meningitis, Meningococcal Meningitis | Phase 1 / Phase 2 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 360 | 2016-08-01 | 2016-09-29 |
| Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 224 | 2016-06-06 | 2018-01-08 |
| A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline - MENINGOCOCCAL INFECTION | Phase 2 | Completed | Pfizer | 400 | 2015-08-01 | 2020-10-26 |
| A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) MenABCWY+OMV vaccine - Meningococcal Disease, Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 129 | 2015-06-30 | 2020-07-09 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 188 | 2015-03-31 | 2022-04-04 |
| Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents Meningococcal ABCWY, Placebo - Meningococcal Disease | Phase 2 | Completed | GlaxoSmithKline | 189 | 2014-12-01 | 2018-09-24 |
Showing 20 of 88. Sign in to see all of them.
Meningitis, Meningococcal (35) · Meningitis (30) · Bacterial Infections (1) · Central Nervous System Infections (1) · Diphtheria (1) · Gram-Negative Bacterial Infections (1) · Haemophilus Infections (1) · Infections (1) · Poliomyelitis (1) · Tetanus (1) · Whooping Cough (1)
Bacterial Infections and Mycoses (88) · Neisseriaceae Infections (88) · Bacterial Infections (87) · Gram-Negative Bacterial Infections (87) · Infections (87) · Nervous System Diseases (48) · Neuroinflammatory Diseases (48) · Central Nervous System Bacterial Infections (35) · Central Nervous System Diseases (35) · Meningitis, Bacterial (35) · Central Nervous System Infections (34) · Meningitis (18) · Actinomycetales Infections (1) · Bordetella Infections (1)
Meningococcal Vaccines (32) · 4CMenB vaccine (11) · Vaccines (9) · Heptavalent Pneumococcal Conjugate Vaccine (6) · Saline Solution (4) · Tetanus Toxoid (4) · tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (4) · MenACWY (3) · MenACWY-CRM vaccine (3) · Rubella Vaccine (3) · diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine (3) · Blood Specimen Collection (2) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (2) · Measles-Mumps-Rubella Vaccine (2) · MenC-CRM vaccine (2)
GlaxoSmithKline (28) · Novartis Vaccines (21) · Sanofi Pasteur, a Sanofi Company (16) · Pfizer (4) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · Sanofi (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Aimei Vacin BioPharm (Zhejiang) Co., Ltd. (1) · Armauer Hansen Research Institute, Ethiopia (1) · Emory University (1) · EyeGene Inc. (1) · JN-International Medical Corporation (1) · Leiden University Medical Center (1) · Medical University of Vienna (1) · Novartis (1)
United States (31) · United Kingdom (14) · Finland (9) · Poland (9) · Belgium (6) · Chile (6) · Germany (6) · Italy (6) · Spain (6) · Australia (4) · Canada (4) · Czechia (4) · Austria (3) · Brazil (3) · China (3)
Abraham Aseffa Aseffa, M.D, PhD (1) · Ahmed Bedru Omer, M.D,Pediatrician (1) · Alberto Yataco, MD (1) · Elizabeth Miller, MD (1) · Francisco Diaz-Mitoma, Dr. (1) · Jeffrey E Atkinson, MD (1) · Leo Visser, MD, PhD (1) · Lin Du (1)
PMID 35257644, PMID 33020485, PMID 35164991, PMID 17287313, PMID 21177912, PMID 30061029, PMID 36369456, PMID 16203934, PMID 16417952, PMID 17065257, PMID 17072120, PMID 17548138, PMID 20844462, PMID 22260988, PMID 22318278, PMID 22394992, PMID 22569484, PMID 23114372, PMID 23352429, PMID 23510357, PMID 23566945, PMID 23958808, PMID 24062178, PMID 24567843, PMID 25077420, PMID 25424810, PMID 25802309, PMID 25969894, PMID 26075813, PMID 26135245, PMID 26237742, PMID 26437712, PMID 26756390, PMID 27642132, PMID 27745812, PMID 29778515, PMID 31110098, PMID 32209248, PMID 32233959, PMID 32233961, PMID 32681472, PMID 34077644, PMID 34787449, PMID 35144847, PMID 36087588, PMID 40043411
2017 (3), 2008 (2), 2009 (2), 2014 (2), 2016 (2), 2023 (1)